



The largest Congress on Allergy and Clinical Immunology delivers a hybrid format in Krakow and online

2021-03-02

Over 8'000 allergy and clinical immunology experts will convene at the EAACI Hybrid Congress 2021, taking place on 10 - 12 July 2021. The new dynamic format will enable participants to join either physically in Krakow, Poland in ICE Kraków Congress Centre or online through the innovative and interactive EAACI Congress & Events Digital Platform.

The EAACI Hybrid Congress 2021 will focus on the theme “Harmonizing research and patient care in allergy, asthma and clinical immunology”. This is one of the overarching priorities for specialists in the field, as only through ensuring standardization and facilitating knowledge mobility can the best degree of care be provided to patients worldwide.

“We have the tools to enable this, ensuring that EAACI guidelines are implemented in clinical and research centres cross-country, advocating for consistency in policies and fostering the allergy specialty to build a dedicated workforce to tackle allergic diseases and asthma. EAACI wants to be present in this continuous effort, and our Congress will provide the setting to stir discussions on the best ways to tackle this challenge.” says Marek Jutel, EAACI President.

This year’s programme has been designed by EAACI’s scientific committee, in a joint effort by Spanish and Polish experts to inspire delegates with more than 40 sessions and six plenary symposia, along with a variety of other session formats, designed to stimulate scientific conversations with exceptional speakers.

“The collaboration between the Spanish and Polish local organising committees in the making of this congress are a perfect representation of what our pan-European Academy stands for, merging the best science from all corners of Europe into an exciting event”, say Joaquin Sastre, Santiago Quirce and Marek Kulus, members of the Local Organising Committee.

The congress will kick-off with a plenary symposium on the morning of **Saturday 10 July** on new frontiers in **asthma**, highlighting the boundaries in getting patients to asthma remission; the utility of asthma guidelines; the landscape of Short-Acting Beta Agonists (SABA) use in Europe; and the shortcomings of biologicals in asthma.

The afternoon plenary symposium will explore real life challenges and successes in **immunotherapy**, to discuss the current state and next generation diagnostics; the current obstacles of immunotherapy treatment; and the future of immunotherapy as we move towards tolerance.

On **Sunday, 11 July**, another two plenary symposia will run. The first will focus on novel pathways for **allergy prevention**, highlighting the mechanisms of farm-like microbiota-derived allergy protection; novel strategies for targeting skin barriers for allergy prevention; assessing how microbial metabolites are protective in allergy; and discussing trained immunity targeted therapeutic approaches in allergy and chronic disease.



The afternoon plenary will focus on news regarding **biologicals** in allergy, focusing on the disease modifying impact of biologicals in asthmatic patients; biomarkers and other predictors of immune response in atopic dermatitis and CRS patients; and the immunological basis of adverse events to biologicals.

On the last day, **Monday 12 July**, a plenary symposium on the topic of **planetary health** will explore the EAACI guidelines on environmental health; describe the effect of airborne microplastic on the lung; and the impacts of wild-fires, pollution, climate change, infections and other threats to the environments.

The afternoon plenary symposium will focus on **novel diagnostic and therapeutic approaches** in allergy and chronic diseases, discussing the concept of AllergoOncology and how IgE monoclonal antibodies can provide therapeutic use in cancer; Immune tolerance approaches to target allergy and autoimmunity; and the utility of JAK-inhibitors in allergy and chronic diseases.

Many new EAACI initiatives will also be presented at the Congress, such as the **EAACI Research an Outreach Network**: a way to navigate through complex European regulations, limited funding opportunities, challenges in data gathering and overall quality control that will prove the position of EAACI as the global leader in promoting and supporting Research and Development.

In addition, the ongoing COVID-19 pandemic has all the more emphasized the need for a harmonized approach towards healthcare worldwide, and has highlighted the challenges faced by different countries, whether it be in terms of resources or the strength and preparedness of each national plan. The congress will also be the perfect opportunity to discuss how the pandemic has impacted the field and the ways to deal with these challenges.

The hybrid format will enable safeguarding the well-being and facilitating the participation of delegates who attend digitally, wherever in the world they are based. Interactive digital platform will ensure that those attending online will have a rich and informative experience, much as those onsite. At the same time, the physical part of the meeting in Krakow will provide delegates with the valuable inter-personal conversations between a top-level pool of experts that make EAACI Congresses so unique.

Join the dynamic dialogue and contribute to the world's largest allergy and clinical immunology event. We look forward to seeing you at the EAACI Hybrid Congress 2021.

About EAACI:

The European Academy of Allergy and Clinical Immunology (EAACI) is an association of clinicians, researchers and allied health professionals founded in 1956. EAACI is dedicated to improving the health of people affected by allergic diseases. With more 12,000 members from 124 countries and



**Magiczny
Kraków**

over 75

National Allergy Societies, EAACI is the primary source of expertise in Europe for all aspects of allergy.

Contact:

EAACI Headquarters

Tel: +41799561865

communications@eaaci.org

www.eaaci.org